I did a quick search.
Ethan B. Russo, Jahan Marcu, in Advances in Pharmacology, 2017
" 2.6 Tetrahydrocannabivarin
Tetrahydrocannabivarin (THCV) is a propyl analogue of THC most often encountered in low concentration in dried plant material, but in THCV-rich plants up to 16% THCV by dry weight has been recorded (Meijer & Hammond, 2005). Mechanistically speaking, THCV can behave as both an agonist and an antagonist at CB1 receptors depending on the concentration (Pertwee, 2008). THCV produces weight loss, and decreases body fat and serum leptin concentrations with increased energy expenditure in obese mice (Cawthorne, Wargent, Zaibi, Stott, & Wright, 2007; Riedel et al., 2009). THCV also demonstrates prominent anticonvulsant properties in rodent cerebellum and pyriform cortex (Hill et al., 2010). THCV appears as a fractional component of many southern African cannabis chemotypes, although plants highly predominant in this agent have been produced (de Meijer et al., 2003; de Meijer & Hammond, 2016). THCV has the CB2-based ability to suppress carageenan-induced hyperalgesia and inflammation, and both phases of formalin-induced pain behavior via CB1 and CB2 in mice (Bolognini et al., 2010).
Antagonizing CB1 receptors can suppress appetite and the intoxicating effects of THC. However, caution must be emphasized when developing CB1 receptor antagonists. Clinical studies in human populations studying the antagonists of CB1 receptors with the drug rimonabant (SR141716A) led to depressive episodes and potentially worsened neurodegenerative disease outcomes, and ultimately this drug was withdrawn from the market (McLaughlin, 2012). Despite this setback, SR141716A remains a very important research tool for unlocking potential medical treatments targeting the CB receptors and deepening the understanding of the ECS. Importantly, the neutral antagonism mechanism of action of THCV seems to be free of the adverse events associated with the CB1 inverse agonists (McPartland, Duncan, Di Marzo, & Pertwee, 2015)."
Now onto the CB2 receptor,
http://www.asaabstracts.com/strands/asaabstracts/abstract.htm?year=2014&index=3&absnum=6489
“Background: Complex regional pain syndrome type 1 (CRPS-I) remains one of the most clinically challenging neuropathic pain syndromes with unclear mechanisms. In the spinal cord, microglial appears to be an initiator of allodynia in neuropathic conditions, and activated microglia express CB2 receptors. Chemokine fractalkine receptor (CX3CR1) is primarily located in the microglia and is essential for neuroinflammation. The role of CX3CR1 and CB2 in CRPS-I remains unknown**.** Currently, there is no effective symptomatic treatment for CRPS-I. Cannabinoid receptor 2 (CB2) agonists have emerged as promising therapy for many neuropathic pain syndromes. MDA7 is a novel selective CB2 agonist. We hypothesized that the CB2 receptor functions in a negative-feedback loop and that early MDA7 administration can blunt the neuroinflammatory response and prevent mechanical allodynia induced by chronic post-ischemic pain (CPIP) through interference with specific signaling pathways in CRPS-I.”
I can follow along with some of the technical language, basically says it may help with Allodynia. Allodynia is a symptom from a number of disorders, makes life real shitty for the people with it. Seems the THCV may help with mechanical Allodynia. In real life terms, it may not hurt to wear clothes again.